Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition

被引:13
|
作者
Ziogos, Efthymios [1 ]
Chelko, Stephen P. [1 ,2 ]
Harb, Tarek [1 ]
Engel, Morgan [2 ]
Vavuranakis, Michael A. [1 ]
Landim-Vieira, Maicon [2 ]
Walsh, Elise M. [3 ,4 ]
Williams, Marlene S. [1 ]
Lai, Shenghan [5 ]
Halushka, Marc K. [3 ]
Gerstenblith, Gary [1 ]
Leucker, Thorsten M. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 600 North Wolfe St, Baltimore, MD 21287 USA
[2] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, 600 North Wolfe St, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ, Sch Med, Dept Genet Med, 600 North Wolfe St, Baltimore, MD 21287 USA
[5] Univ Maryland, Sch Med, Inst Human Virol, Dept Epidemiol & Publ Hlth, 660 Redwood St, Baltimore, MD 21201 USA
关键词
PCSK9; Platelets; Endothelial Cells; ACS; inhibition; SUBTILISIN/KEXIN TYPE 9; VON-WILLEBRAND-FACTOR; EARLY POSTINFARCTION PERIOD; PLATELET-FACTOR-4; EXPRESSION; SELECTIN; MARKERS; DISEASE;
D O I
10.1093/ehjcvp/pvad051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Platelet activation and endothelial dysfunction contribute to adverse outcomes in patients with acute coronary syndromes (ACS). The goals of this study were to assess the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition on markers of platelet activation and endothelial dysfunction in ACS patients and the interaction among PCSK9, platelets, and endothelial cells (ECs) on left internal mammary artery (LIMA) vascular endothelium using specimens obtained during coronary arter y bypass surgery (CABG). Methods and Results Acute coronary syndromes patients enrolled in the Evolocumab in ACS trials were randomized to placebo or a single dose of 420 mg evolocumab within 24 h of hospitalization. Serum samples for analysis of platelet factor 4 (PF4) and P-selectin, markers of platelet activation, and von Willebrand factor (vWF), a marker of endothelial dysfunction, were obtained at baseline and 30 days. Additionally, LIMA segments obtained during CABG from patients who were and were not receiving evolocumab were immunostained with PCSK9; CD61, a platelet-specific marker; and CD31, an endothelial cell-specific marker. Forty-six participants were randomized to placebo or to evolocumab. Controlling for baseline levels, PF4 and vWF were significantly lower in the evolocumab, than in the placebo, group at 30 days. Immunostaining of LIMA specimens from twelve participants undergoing CABG revealed colocalization of PCSK9, CD61, and CD31 at the vascular endothelium. Administration of evolocumab was associated with decreased overlap of PCSK9, CD61, and CD31. Conclusions Proprotein Convertase Subtilisin/Kexin 9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction. [GRAPHICS]
引用
收藏
页码:636 / 646
页数:11
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
    Ziogos, E.
    Chelko, S. P.
    Walsh, E.
    Engel, M.
    Gerstenblith, G.
    Halushka, M. K.
    Leucker, T. M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1281 - 1281
  • [2] PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
    Zulkapli, Rahayu
    Abd Muid, Suhaila
    Wang, Seok Mui
    Nawawi, Hapizah
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [3] PCSK9 as a Positive Modulator of Platelet Activation
    Camera, Marina
    Rossetti, Laura
    Barbieri, Silvia S.
    Zanotti, Ilaria
    Canciani, Barbara
    Trabattoni, Daniela
    Ruscica, Massimiliano
    Tremoli, Elena
    Ferri, Nicola
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (08) : 952 - 954
  • [4] Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
    Nayarese, Eliano P.
    Kolodziejczak, Michalina
    Winter, Max-Paul
    Alimohammadi, Arman
    Lang, Irene M.
    Buffon, Antonino
    Lip, Gregory Y. H.
    Siller-Matula, Jolanta M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 644 - 649
  • [5] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [6] Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome
    Giordano, Salvatore
    Ielapi, Jessica
    Salerno, Nadia
    Cersosimo, Angelica
    Lucchino, Alessandro
    Laschera, Alessandro
    Canino, Giovanni
    Di Costanzo, Assunta
    De Rosa, Salvatore
    Torella, Daniele
    Sorrentino, Sabato
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (10)
  • [7] PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
    Chen, Hongzhen
    Chen, Xiaomin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [8] PCSK9: A NOVEL MEDIATOR FOR HIV-INDUCED CORONARY ARTERY ENDOTHELIAL DYSFUNCTION
    Leucker, Thorsten
    Schar, Michael
    Iantorno, Micaela
    Moore, Richard
    Weiss, Robert
    Gerstenblith, Gary
    Hays, Allison
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 2028 - 2028
  • [9] PCSK9 inhibition might increase endothelial inflammation
    Schmid, Johannes A.
    ATHEROSCLEROSIS, 2022, 362 : 26 - 28
  • [10] Early Use of PCSK9 Inhibitors in the Prognosis of Patients with Acute Coronary Syndrome by Protecting Vascular Endothelial Function
    Xu, Linghao
    Wang, Yuanqi
    Wang, Yiqiong
    Wang, Liang
    Du, Peizhao
    Cheng, Jing
    Zhang, Chunsheng
    Jiao, Tiantian
    Xing, Lijian
    Tapu, Md Sakibur Rahman
    Jia, Haonan
    Li, Jiming
    PHARMACOLOGY, 2024,